Synbiotic VSL#3 and yacon-based product modulate the intestinal microbiota and prevent the development of pre-neoplastic lesions in a colorectal carcinogenesis model
- PMID: 32902682
- DOI: 10.1007/s00253-020-10863-x
Synbiotic VSL#3 and yacon-based product modulate the intestinal microbiota and prevent the development of pre-neoplastic lesions in a colorectal carcinogenesis model
Abstract
Colorectal cancer is a public health problem, with dysbiosis being one of the risk factors due to its role in intestinal inflammation. Probiotics and synbiotics have been used in order to restore the microbiota balance and to prevent colorectal carcinogenesis. We aimed to investigate the effects of the probiotic VSL#3® alone or in combination with a yacon-based prebiotic concentrate on the microbiota modulation and its influence on colorectal carcinogenesis in an animal model. C57BL/6J mice were divided into three groups: control (control diet), probiotic (control diet + VSL#3®), and synbiotic (yacon diet + VSL#3®). The diets were provided for 13 weeks and, from the third one, all animals were subjected to induction of colorectal cancer precursor lesions. Stool samples were collected to evaluate organic acids, feces pH, β-glucuronidase activity, and microbiota composition. The colon was used to count pre-neoplastic lesions and to determine the cytokines. The microbiota composition was influenced by the use of probiotic and synbiotic. Modifications were also observed in the abundance of bacterial genera with respect to the control group, which confirms the interference of carcinogenesis in the microbiota. Pre-neoplastic lesions were reduced by the use of the synbiotic, but not with the probiotic. The protection provided by the synbiotic can be attributed to the modulation of the intestinal inflammatory response, to the inhibition of a pro-carcinogenic enzyme, and to the production of organic acids. The modulation of the composition and activity of the microbiota contributed to beneficial changes in the intestinal microenvironment, which led to a reduction in carcinogenesis. KEY POINTS: • Synbiotic reduces the incidence of colorectal cancer precursor lesions. • Synbiotic modulates the composition and activity of intestinal microbiota. • Synbiotic increases the abundance of butyrate-producing bacteria.
Keywords: Colorectal cancer; Gut microbiota; Prebiotic; Probiotic; Synbiotic.
Similar articles
-
Evaluation of the efficacy of probiotic VSL#3 and synbiotic VSL#3 and yacon-based product in reducing oxidative stress and intestinal permeability in mice induced to colorectal carcinogenesis.J Food Sci. 2021 Apr;86(4):1448-1462. doi: 10.1111/1750-3841.15690. Epub 2021 Mar 24. J Food Sci. 2021. PMID: 33761141
-
Use of the synbiotic VSL#3 and yacon-based concentrate attenuates intestinal damage and reduces the abundance of Candidatus Saccharimonas in a colitis-associated carcinogenesis model.Food Res Int. 2020 Nov;137:109721. doi: 10.1016/j.foodres.2020.109721. Epub 2020 Sep 25. Food Res Int. 2020. PMID: 33233290
-
Synbiotic modulates intestinal microbiota metabolic pathways and inhibits DMH-induced colon tumorigenesis through c-myc and PCNA suppression.Food Res Int. 2022 Aug;158:111379. doi: 10.1016/j.foodres.2022.111379. Epub 2022 Jun 14. Food Res Int. 2022. PMID: 35840186
-
Preclinical and clinical relevance of probiotics and synbiotics in colorectal carcinogenesis: a systematic review.Nutr Rev. 2020 Aug 1;78(8):667-687. doi: 10.1093/nutrit/nuz087. Nutr Rev. 2020. PMID: 31917829
-
Effects of prebiotics, probiotics, and synbiotics on the infant gut microbiota and other health outcomes: A systematic review.Crit Rev Food Sci Nutr. 2023;63(22):5620-5642. doi: 10.1080/10408398.2021.2022595. Epub 2022 Jan 4. Crit Rev Food Sci Nutr. 2023. PMID: 37667870 Free PMC article. Review.
Cited by
-
Beneficial Effect of Synbiotic Combination of Limosilactobacillus fermentum FS-10, Lactiplantibacillus plantarum Lp1-IC and Short-Chain Fructooligosaccharides in Colitis Murine Model.Probiotics Antimicrob Proteins. 2024 Jul 10. doi: 10.1007/s12602-024-10320-5. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 38985387
-
The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer.Front Cell Dev Biol. 2021 Aug 12;9:631552. doi: 10.3389/fcell.2021.631552. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34458248 Free PMC article. Review.
-
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intest Res. 2024 Jan;22(1):15-43. doi: 10.5217/ir.2023.00080. Epub 2023 Nov 8. Intest Res. 2024. PMID: 37935653 Free PMC article. Review.
-
Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy.Front Immunol. 2024 Nov 29;15:1442788. doi: 10.3389/fimmu.2024.1442788. eCollection 2024. Front Immunol. 2024. PMID: 39676876 Free PMC article. Review.
-
Association between Probiotics and Modulation of Gut Microbial Community Composition in Colorectal Cancer Animal Models: A Systematic Review (2010-2021).Can J Infect Dis Med Microbiol. 2023 Sep 9;2023:3571184. doi: 10.1155/2023/3571184. eCollection 2023. Can J Infect Dis Med Microbiol. 2023. PMID: 37719797 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical